NEW YORK (Reuters Health) – A finding of homozygosity for mutations that cause Gaucher disease in patients who report no symptoms of the disorder warrants further followup. Manifestations…
NEW YORK (Reuters Health) – As is seen in certain other gastrointestinal illnesses, the prevalence of low-trauma fractures is higher among patients with chronic pancreatitis than in the…
NEW YORK (Reuters Health) – Gynecologic side effects of the third-generation selective estrogen receptor modulator lasofoxifene are generally acceptable, researchers report, and “contribute to an overall favorable benefit-risk…
NEW YORK (Reuters Health) – Revised guidelines on the prevention and treatment of osteoporosis related to glucocorticoid use recommend bisphosphonate therapy but withdraw endorsement of testosterone and estrogen…
NEW YORK (Reuters Health) – Updated guidelines issued by the American Society of Clinical Oncology (ASCO) recommend that postmenopausal women with hormone receptor-positive breast cancer should receive aromatase…
NEW YORK (Reuters Health) – HIV-positive patients taking efavirenz are at risk for clinically significant vitamin D deficiency, and for excessive bone turnover if they are taking tenofovir,…
NEW YORK (Reuters Health) – Children receiving the bisphosphonate pamidronate for severe bone demineralization have a prolonged corrected QT interval (QTc), French researchers report online May 25th in…
NEW YORK (Reuters Health) – Statins do not reduce fracture risk or increase bone mineralization in postmenopausal women, according to a systematic review of randomized controlled trials (RCTs).…
NEW YORK (Reuters Health) – Rib fractures in older men are often associated with risk markers for osteoporosis, such as low bone density and a history of fracture,…
NEW YORK (Reuters Health) – In postmenopausal women with osteoporosis, the selective estrogen-receptor modulator lasofoxifene cuts the risks of fractures, estrogen-receptor-positive breast cancer, coronary disease, and stroke, the…